Milestone in osteoarthritis research
Researchers found new genetic risk factors for osteoarthritis and identified novel drug targets. Their finding is a milestone towards the development of the first ever curative treatment for osteoarthritis. The study involved an international consortium led by Helmholtz Zentrum München.
| The Genetic Burden of Osteoarthritis © Cindy Boer |
Helmholtz Association of German Research Centres, August 26, 2021
Osteoarthritis is a disease of the joints and affects over 300 million individuals worldwide. It is characterized by a gradually increasing degeneration of the cartilage on the joint surface. This results in chronic pain and stiffness in the joints and is a leading cause of disability. Until today, no curative treatments are available. An improved understanding of what causes the disease and the development of novel treatments are therefore urgently needed and eagerly anticipated by patients.
| The power of large studies |
In the largest study of osteoarthritis to date (across over 825,000 individuals from 9 populations), an international team of researchers led by Helmholtz Zentrum München discovered new genetic risk factors for the disease and identified high-value drug targets.
This study provides a stepping stone for translating genetic discoveries into osteoarthritis drug development, ultimately helping to catalyze an improvement in the lives of patients suffering from osteoarthritis. “This is a major step forward in understanding this debilitating disease and could not have been achieved without this international team effort,” said Eleftheria Zeggini, Director of the Institute of Translational Genomics at Helmholtz Zentrum München and professor at the Technical University of Munich.
| Unravelling the secrets of osteoarthritis |
The researchers also found previously unknown differences in disease risk for weight-bearing and non-weight-bearing joints, the first ever female-specific risk factors for developing disease, and the first risk factors for early-onset disease. For the first time, they found genetic links between osteoarthritis and its main symptom, pain.
“Because we have investigated osteoarthritis in multiple joints, we have also identified specific genetic changes that underpin the risk for all forms of osteoarthritis. Some of these genes may prove to be validated as therapeutic targets for osteoarthritis, regardless of the joint affected”, says Cindy Boer from Erasmus MC University Medical Center in the Netherlands, co-first author of the article.
| Identifying new drug targets |
By combining multiple lines of evidence, the researchers pinpointed likely causal genes for osteoarthritis that constitute potential drug targets for the disease. Many of the implicated genes code for molecules that are the targets of approved (licensed) drugs and drugs in clinical development. These findings substantially strengthen the evidence for these potential therapeutics and provide novel drug repositioning opportunities.
| Future work |
This work provides a robust springboard for follow-up functional and clinical studies. These are necessary to elucidate how to target the implicated genes and proteins, and, ultimately, how these interventions will affect disease outcome in the patient.
| About the consortium |
This study is the first output of the “Genetics of Osteoarthritis” consortium, a global collaboration with a focus on progressing our understanding of the genetic underpinning of osteoarthritis and related traits. The consortium aims to bring together all globally available genetic studies of osteoarthritis in order to make new discoveries possible. It is led by Helmholtz Zentrum München.
Source Helmholtz Zentrum München via Medical Xpress
| References |
Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations, Boer CG, Hatzikotoulas K, Southam L, Stefánsdóttir L, Zhang Y, Coutinho de Almeida R, Wu TT, Zheng J, Hartley A, Teder-Laving M, Skogholt AH, Terao C, Zengini E, Alexiadis G, Barysenka A, Bjornsdottir G, Gabrielsen ME, Gilly A, Ingvarsson T, Johnsen MB, Jonsson H, Kloppenburg M, Luetge A, Lund SH, Mägi R, Mangino M, Nelissen RRGHH, Shivakumar M, Steinberg J, Takuwa H, Thomas LF, Tuerlings M; arcOGEN Consortium; HUNT All-In Pain; ARGO Consortium; Regeneron Genetics Center, Babis GC, Cheung JPY, Kang JH, Kraft P, Lietman SA, Samartzis D, Slagboom PE, Stefansson K, Thorsteinsdottir U, Tobias JH, Uitterlinden AG, Winsvold B, Zwart JA, Davey Smith G, Sham PC, Thorleifsson G, Gaunt TR, Morris AP, Valdes AM, Tsezou A, Cheah KSE, Ikegawa S, Hveem K, Esko T, Wilkinson JM, Meulenbelt I, Lee MTM, van Meurs JBJ, Styrkársdóttir U, Zeggini E. Cell. 2021 Sep 2;184(18):4784-4818.e17. doi: 10.1016/j.cell.2021.07.038. Epub 2021 Aug 26. Full text
